Biotech Values

[DewDiligence]

Do you see ITMN as a good short candidate? …There seems to be nothing in the pipeline worth the market cap.

It wouldn’t be my kind of short because you could lose big if the EU’s CHMP approved pirfenidone with a favorable label. Moreover, the timing of CHMP actions are harder to gauge than FDA actions.